Health Check: CSL places $500m-plus bet on rare kidney and liver disease drug candidate | Stockhead

CSL will pay an upfront US$355 million ($515m) to co-develop an external drug candidate aimed at treating rare kidney and liver diseases.

Continue in Briflio to read, react, comment, and share.